论文部分内容阅读
目的探讨骨肉瘤组织中p97的表达与远处转移的关系。方法运用免疫组织化学SP法检测60例普通型骨肉瘤组织p97的表达情况,21例骨软骨瘤组织作为对照。结合临床随访结果,判断p97表达与骨肉瘤远处转移病例之间的关系。结果60例普通型骨肉瘤组织中p97低表达24(40.0%)例,中度表达10(16.7%)例,高表达26(43.3%)例;21例骨软骨瘤组织中p97低表达14(66.6%)例,中度表达6(28.6%)例,高表达1(4.8%)例,二者统计学差异明显(P<0.01)。14例发生远处转移的骨肉瘤组织中p97低表达2(14.3%)例,中度表达1(7.1%)例,高表达11(78.6%)例;46例无远处转移的骨肉瘤组织中p97低表达22(47.8%)例,中度表达9(19.6%)例,高表达15(32.6%)例,二者统计学差异显著(P=0.010),尤其低表达与高表达比较差异更明显(P<0.01)。但是,p97的表达与组织学类型无明显的相关性(P>0.05)。结论p97可能参与了骨肉瘤发生与远处转移,这提示p97检测可能成为判断骨肉瘤发生远处转移的一项有价值的指标;同时p97为骨肉瘤的诊疗提供一种新的可能分子靶标和途径。
Objective To investigate the relationship between p97 expression and distant metastasis in osteosarcoma. Methods Immunohistochemical SP method was used to detect the expression of p97 in 60 cases of osteosarcoma and 21 cases of osteochondroma as control. Combined with clinical follow-up results to determine the relationship between p97 expression and distant metastasis of osteosarcoma cases. Results The expression of p97 was low in 24 cases (40.0%) in 60 osteosarcoma tissues, 10 (16.7%) moderately expressed and 26 (43.3%) highly expressed in osteosarcoma tissues. The expression of p97 was low in 14 66.6%). There were 6 cases with moderate expression (28.6%) and 1 case with high expression (4.8%), the difference was statistically significant (P <0.01). In 14 cases of osteosarcoma with distant metastasis, the expression of p97 was low in 2 (14.3%) cases, 1 (7.1%) moderately expressed and 11 (78.6%) highly expressed in osteosarcoma; 46 cases of osteosarcoma without distant metastasis The expression of p97 was low in 22 (47.8%) cases, 9 (19.6%) moderately expressed and 15 (32.6%) highly expressed (P = 0.010), especially in low expression and high expression More obvious (P <0.01). However, there was no significant correlation between p97 expression and histological type (P> 0.05). Conclusions p97 may be involved in the occurrence and distant metastasis of osteosarcoma, suggesting that p97 detection may be a valuable indicator for distant metastasis of osteosarcoma. Meanwhile, p97 provides a new possible molecular target for the diagnosis and treatment of osteosarcoma and way.